Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
1 Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), The Netherlands and 2 German GMMG Correspondence: H.M. Lokhorst, Dept. of Hematology, University Medical Center, Utrecht, The Netherlands. E-mail: h.lokhorst{at}umcutrecht.nl In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients rando...
Saved in:
| Published in: | Haematologica (Roma) Vol. 93; no. 1; pp. 124 - 127 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Pavia
Haematologica
01-01-2008
Ferrata Storti Foundation |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | 1 Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), The Netherlands and 2 German GMMG
Correspondence: H.M. Lokhorst, Dept. of Hematology, University Medical Center, Utrecht, The Netherlands. E-mail: h.lokhorst{at}umcutrecht.nl
In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p <0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m 2 response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p <0.001). CTC grade 3–4 adverse events were similar in both arms.
Key words: thalidomide, untreated multiple myeloma. |
|---|---|
| AbstractList | In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms. In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms. 1 Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), The Netherlands and 2 German GMMG Correspondence: H.M. Lokhorst, Dept. of Hematology, University Medical Center, Utrecht, The Netherlands. E-mail: h.lokhorst{at}umcutrecht.nl In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p <0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m 2 response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p <0.001). CTC grade 3–4 adverse events were similar in both arms. Key words: thalidomide, untreated multiple myeloma. |
| Author | Schlenzka, Jana van Oers, Marinus H.J Schmidt-Wolf, Ingo van der Holt, Bronno Zweegman, Sonja Goldschmidt, Hartmut Schaafsma, Ron Delforge, Michel Naumann, Ralph Salwender, Hans-Juergen Croockewit, Sandra Sonneveld, Pieter de Weerdt, Okke for Dutch-Belgian HOVON and German GMMG Breitkreutz, Iris Blau, Igor Wijermans, Pierre Lokhorst, Henk M Bos, Gerard M.J Bertsch, Uta Duersen, Ulrich Sinnige, Harm Vellenga, Edo Martin, Hans Scheid, Christof Wittebol, Shulamiet Barge, Rene Joosten, Peter van Marwijk-Kooy, Marinus |
| Author_xml | – sequence: 1 fullname: Lokhorst, Henk M – sequence: 2 fullname: Schmidt-Wolf, Ingo – sequence: 3 fullname: Sonneveld, Pieter – sequence: 4 fullname: van der Holt, Bronno – sequence: 5 fullname: Martin, Hans – sequence: 6 fullname: Barge, Rene – sequence: 7 fullname: Bertsch, Uta – sequence: 8 fullname: Schlenzka, Jana – sequence: 9 fullname: Bos, Gerard M.J – sequence: 10 fullname: Croockewit, Sandra – sequence: 11 fullname: Zweegman, Sonja – sequence: 12 fullname: Breitkreutz, Iris – sequence: 13 fullname: Joosten, Peter – sequence: 14 fullname: Scheid, Christof – sequence: 15 fullname: van Marwijk-Kooy, Marinus – sequence: 16 fullname: Salwender, Hans-Juergen – sequence: 17 fullname: van Oers, Marinus H.J – sequence: 18 fullname: Schaafsma, Ron – sequence: 19 fullname: Naumann, Ralph – sequence: 20 fullname: Sinnige, Harm – sequence: 21 fullname: Blau, Igor – sequence: 22 fullname: Delforge, Michel – sequence: 23 fullname: de Weerdt, Okke – sequence: 24 fullname: Wijermans, Pierre – sequence: 25 fullname: Wittebol, Shulamiet – sequence: 26 fullname: Duersen, Ulrich – sequence: 27 fullname: Vellenga, Edo – sequence: 28 fullname: Goldschmidt, Hartmut – sequence: 29 fullname: for Dutch-Belgian HOVON and German GMMG |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20010816$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18166796$$D View this record in MEDLINE/PubMed |
| BookMark | eNpFkU1r3DAQhk1JaTZprz0WXdqbt_qwLftYQpsEAr2kZzGWxrsKsuVKcpb9L_mx1X40gQFJo2fel-G9Ki4mP2FRfGZ0LQSvvm8BR0jerRlrqupdsWJ1x8tWcnZRrKjoaNlQ2V4WVzE-Ucpp18kPxSVrWdPIrlkVL49bcNb40RokdsplFp2sn0gKCGnEKeWezveIkaQtkmcMe7Lx3pAZQrLgSMA4-ykiCZCQ9Dj4gAQmQ2BIGMjWbral8fk_jweY9wefOeCz9Ut0e7JMRys0ZFxcsrNDMu7R-RE-Fu8HcBE_nc_r4s-vn483d-XD79v7mx8Ppa7qLpVSDiCo0YLXdS7Zo8AGJK8Fqxi2AIZBJ9nQsr6qetoi1z0dAPOTtm0nxHVxf9I1Hp7UHOwIYa88WHVs-LBRh1W1Q6UN1ryRg2FcVtmu5XowNWtRNJK1mmWtbyetOfi_C8akRhs1OgcT5n2VpEw2VSMzuD6BOvgYAw6vxoyqQ7bqf7bqmG0e-HJWXvoRzRt-DjMDX88ARA1uCDBpG185TimjmX3jDsnsbEAVR3Auy3K12-06oZhivBL_AH7jwI4 |
| CitedBy_id | crossref_primary_10_1002_hon_1019 crossref_primary_10_1182_asheducation_2008_1_306 crossref_primary_10_1182_asheducation_V2013_1_496_3847117 crossref_primary_10_1007_s00277_014_2067_3 crossref_primary_10_1016_S1658_3876_09_50006_4 crossref_primary_10_1038_bmt_2010_283 crossref_primary_10_3816_CLML_2010_n_076 crossref_primary_10_1016_j_bbmt_2014_03_001 crossref_primary_10_1016_j_jval_2013_12_009 crossref_primary_10_1016_j_blre_2010_03_001 crossref_primary_10_1002_hon_2199 crossref_primary_10_1016_j_bbmt_2009_02_013 crossref_primary_10_1179_1973947812Y_0000000004 crossref_primary_10_1182_blood_2010_03_273706 crossref_primary_10_1200_JCO_2007_15_2546 crossref_primary_10_3390_cancers14235759 crossref_primary_10_1111_j_1600_0609_2010_01472_x crossref_primary_10_1097_CCO_0b013e3283136984 crossref_primary_10_1182_asheducation_V2012_1_335_3792205 crossref_primary_10_1159_000442511 crossref_primary_10_1182_blood_2009_07_204651 crossref_primary_10_1001_jamaoncol_2018_2961 crossref_primary_10_1586_14737140_8_10_1569 crossref_primary_10_1182_blood_2009_12_258830 crossref_primary_10_1182_asheducation_2013_1_496 crossref_primary_10_1016_S2352_3026_18_30149_2 crossref_primary_10_1016_j_bbmt_2008_10_006 crossref_primary_10_3109_10428194_2012_751528 crossref_primary_10_1182_blood_2009_07_235531 crossref_primary_10_1111_bjh_12410 crossref_primary_10_1016_j_ejca_2012_06_010 crossref_primary_10_1182_blood_2009_08_238196 crossref_primary_10_3109_07357907_2015_1081690 crossref_primary_10_1517_14656560802636839 crossref_primary_10_1111_j_1365_2141_2009_07649_x crossref_primary_10_1111_j_1600_0609_2008_01127_x crossref_primary_10_1111_j_1600_0609_2010_01431_x crossref_primary_10_1016_j_bbmt_2009_10_006 crossref_primary_10_1182_blood_2009_05_222539 crossref_primary_10_1182_blood_2011_05_355081 crossref_primary_10_3816_CLML_2010_n_007 crossref_primary_10_1016_j_leukres_2013_06_019 crossref_primary_10_1200_JCO_2009_27_9158 crossref_primary_10_3109_07357907_2013_840382 crossref_primary_10_1007_s00277_016_2897_2 crossref_primary_10_1016_j_bbmt_2016_06_004 crossref_primary_10_1182_blood_2012_05_423202 crossref_primary_10_1097_PPO_0b013e3181c51ca3 crossref_primary_10_1016_S1557_9190_11_70823_X crossref_primary_10_1007_s11899_011_0083_0 crossref_primary_10_1177_107327481101800406 crossref_primary_10_1586_era_09_52 crossref_primary_10_3904_kjim_2013_28_3_263 crossref_primary_10_1038_leusup_2013_2 crossref_primary_10_1038_leusup_2013_4 crossref_primary_10_1179_acb_2010_055 crossref_primary_10_1007_s11899_010_0057_7 crossref_primary_10_1097_MOH_0b013e32832e3154 crossref_primary_10_1182_asheducation_2009_1_555 crossref_primary_10_1200_JCO_2008_21_1060 crossref_primary_10_1038_bmt_2010_75 crossref_primary_10_1016_S0140_6736_09_60221_X crossref_primary_10_3904_kjim_2015_30_5_675 crossref_primary_10_3724_SP_J_1206_2008_00307 crossref_primary_10_1007_s00415_009_0127_8 crossref_primary_10_1053_j_seminoncol_2013_07_006 crossref_primary_10_1111_j_1365_2796_2010_02324_x crossref_primary_10_1093_annonc_mdn314 crossref_primary_10_1182_blood_2009_04_205013 crossref_primary_10_1155_2016_6848902 crossref_primary_10_1016_j_clml_2011_03_026 crossref_primary_10_1038_leu_2011_346 crossref_primary_10_1053_j_seminhematol_2009_02_005 crossref_primary_10_1177_1078155208101096 crossref_primary_10_1586_ehm_12_49 crossref_primary_10_1016_j_bbmt_2012_08_011 crossref_primary_10_1053_j_seminhematol_2009_02_006 crossref_primary_10_2217_ijr_09_9 crossref_primary_10_1038_bmt_2010_101 crossref_primary_10_1007_s00259_009_1199_5 crossref_primary_10_1093_annonc_mds311 crossref_primary_10_5581_1516_8484_20140020 crossref_primary_10_4065_mcp_2009_0603 crossref_primary_10_1016_S1155_1984_12_50916_7 crossref_primary_10_1016_j_critrevonc_2012_12_011 crossref_primary_10_1007_s12185_015_1846_5 crossref_primary_10_1016_j_clml_2012_08_007 crossref_primary_10_1016_j_critrevonc_2013_05_012 crossref_primary_10_1002_ajh_23835 crossref_primary_10_1002_hon_832 crossref_primary_10_1007_s00108_018_0527_x crossref_primary_10_3109_10428194_2012_717277 crossref_primary_10_1016_j_ejca_2009_07_006 crossref_primary_10_1097_PPO_0b013e3181c51cd4 crossref_primary_10_1016_S0305_7372_10_70006_2 crossref_primary_10_2165_11585930_000000000_00000 crossref_primary_10_3390_cancers11122015 crossref_primary_10_1182_blood_2009_03_201053 crossref_primary_10_1080_17474086_2021_1905513 crossref_primary_10_1182_blood_2009_12_257519 crossref_primary_10_1016_j_bbmt_2009_03_012 crossref_primary_10_1111_j_1600_0609_2008_01179_x crossref_primary_10_1002_cncr_28325 crossref_primary_10_1200_JCO_2010_32_5878 crossref_primary_10_1016_j_htct_2019_05_004 crossref_primary_10_1634_theoncologist_2009_0203 crossref_primary_10_1517_14728210802676278 |
| ContentType | Journal Article |
| Copyright | 2008 INIST-CNRS |
| Copyright_xml | – notice: 2008 INIST-CNRS |
| CorporateAuthor | Dutch-Belgian HOVON German GMMG for Dutch-Belgian HOVON and German GMMG |
| CorporateAuthor_xml | – name: Dutch-Belgian HOVON – name: German GMMG – name: for Dutch-Belgian HOVON and German GMMG |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 DOA |
| DOI | 10.3324/haematol.11644 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1592-8721 |
| EndPage | 127 |
| ExternalDocumentID | oai_doaj_org_article_cde5267fd127455282cfd518e36718c1 10_3324_haematol_11644 18166796 20010816 www93_1_124 |
| Genre | Randomized Controlled Trial Clinical Trial, Phase III Journal Article |
| GroupedDBID | - 29I 2WC 53G 5GY 5RE 5VS ABFLS ADACO ADBBV AENEX AGCAB ALMA_UNASSIGNED_HOLDINGS BAWUL BCNDV C1A CS3 DIK E3Z EBS EJD F5P FRP GROUPED_DOAJ H13 KQ8 M~E O0- OK1 P2P RHF RHI RNS RPM SJN TFS WOQ WOW ZA5 --- AAFWJ AFPKN AOIJS BTFSW HYE IQODW SV3 TR2 UDS W8F CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c459t-77fa30dc32552557be3e6a7253141e8aad1a971f81b44b08e2cb0fae1b4088933 |
| IEDL.DBID | DOA |
| ISSN | 0390-6078 |
| IngestDate | Tue Oct 22 15:16:10 EDT 2024 Fri Oct 25 11:27:17 EDT 2024 Thu Nov 21 23:40:35 EST 2024 Tue Oct 15 23:33:44 EDT 2024 Sun Oct 22 16:05:52 EDT 2023 Tue Jan 05 20:16:40 EST 2021 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Antineoplastic agent Immunopathology Hematology Response rate Malignant hemopathy Myeloma Anti-Tumor Necrosis Factor-alpha Induction treatment Immunoglobulinopathy Partial Lymphoproliferative syndrome High dose Thalidomide Cancer untreated multiple myeloma |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c459t-77fa30dc32552557be3e6a7253141e8aad1a971f81b44b08e2cb0fae1b4088933 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-News-3 content type line 23 |
| OpenAccessLink | https://doaj.org/article/cde5267fd127455282cfd518e36718c1 |
| PMID | 18166796 |
| PQID | 70176467 |
| PQPubID | 23479 |
| PageCount | 4 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_cde5267fd127455282cfd518e36718c1 proquest_miscellaneous_70176467 crossref_primary_10_3324_haematol_11644 pubmed_primary_18166796 pascalfrancis_primary_20010816 highwire_smallpub2_www93_1_124 |
| ProviderPackageCode | RHF RHI |
| PublicationCentury | 2000 |
| PublicationDate | 2008-01-00 |
| PublicationDateYYYYMMDD | 2008-01-01 |
| PublicationDate_xml | – month: 01 year: 2008 text: 2008-01-00 |
| PublicationDecade | 2000 |
| PublicationPlace | Pavia |
| PublicationPlace_xml | – name: Pavia – name: Italy |
| PublicationTitle | Haematologica (Roma) |
| PublicationTitleAlternate | Haematologica |
| PublicationYear | 2008 |
| Publisher | Haematologica Ferrata Storti Foundation |
| Publisher_xml | – name: Haematologica – name: Ferrata Storti Foundation |
| References | Haematologica. 2008 Mar;93(3):480 |
| References_xml | |
| SSID | ssj0020997 |
| Score | 2.3190353 |
| Snippet | 1 Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), The Netherlands and 2 German GMMG
Correspondence: H.M. Lokhorst, Dept. of Hematology, University... In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response... |
| SourceID | doaj proquest crossref pubmed pascalfrancis highwire |
| SourceType | Open Website Aggregation Database Index Database Publisher |
| StartPage | 124 |
| SubjectTerms | Adult Aged Angiogenesis Inhibitors - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cytarabine - therapeutic use Daunorubicin - therapeutic use Dexamethasone - therapeutic use Female Hematologic and hematopoietic diseases Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical Oncology - methods Medical sciences Middle Aged Multiple Myeloma - drug therapy Remission Induction Thalidomide - therapeutic use Thioguanine - therapeutic use Treatment Outcome Vincristine - therapeutic use |
| Title | Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma |
| URI | http://www.haematologica.org/cgi/content/abstract/93/1/124 https://www.ncbi.nlm.nih.gov/pubmed/18166796 https://search.proquest.com/docview/70176467 https://doaj.org/article/cde5267fd127455282cfd518e36718c1 |
| Volume | 93 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgB8QFQcvHtlB8QHCKmu-PY4FWvcCFInGznMyEVsomq6arVf4LP7Zv7M1CD4gLUi7JWvHaM7bfxM9vlHrHURtTxATnDW2QUlYEFqYPSoa9bVnaJpOzwxffiq8_ys9nIpOzS_UlnDAvD-w77qQhzuK8aClC_JRliBCalrII78oxrTY-8AnzOZjahlpyHtTtH1QIjrAKernGBOjh5MqKGOrQYbIAFri3HDnV_j-UgoUoaUf0VeuTXPwdhbrV6PyperKFkfrU__1n6gH3--rgtEeVy0m_147Y6b6Y76tHX7b75wfq1-UVcDcNy2tifd3jIq8eq3eEczwTIDnyqIENNTx90j-HgfRK-gp13nhWLWsRmdA1A_Wytj1pl25cS6sCGvC7P9o1ST0rIRMP67Gb9Lp3VTHpmcuolxN3w9I-V9_Pzy4_XQTb_AxBk2bVLYB5a5OQmgRhCa6i5oRzW8QY1mnEpbUU2aqIWiDjNK3DkuOmDlvLuBVyVZK8UHv90PMrpSmjmGxbYAKq0hqgtXGBZhaGTYuitFAfZjOZlZfhMAhfxKBmNqhxBl2oj2LFXSmRz3YP4FRm61TmX061UMezD5hxabsOto7NZrOpEhMZQCIUuOcZu-qEoia5TBbq7ewqBgNWdmFsz-hoU2AOzLE8LdRL70G_GyR7uEWVH_6PJhypx57aIl-LXqu925s1v1EPR1ofu6FyB7RbGoU |
| link.rule.ids | 315,782,786,866,2106,27933,27934 |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Thalidomide+in+induction+treatment+increases+the+very+good+partial+response+rate+before+and+after+high-dose+therapy+in+previously+untreated+multiple+myeloma&rft.jtitle=Haematologica+%28Roma%29&rft.au=Lokhorst%2C+Henk+M&rft.au=Schmidt-Wolf%2C+Ingo&rft.au=Sonneveld%2C+Pieter&rft.au=van+der+Holt%2C+Bronno&rft.date=2008-01-01&rft.eissn=1592-8721&rft.volume=93&rft.issue=1&rft.spage=124&rft.epage=127&rft_id=info:doi/10.3324%2Fhaematol.11644&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0390-6078&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0390-6078&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0390-6078&client=summon |